Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01213238 · ClinicalTrials.gov registry record · Phase 1
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT01213238: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01213238 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 116 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01213238, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to patients with advanced cancer that has spread to the liver. The safety of these drug combinations will also be studied.
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- DRUG Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2010-09-30 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01213238
The ClinicalTrials.gov registry entry for NCT01213238 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01213238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01213238 about?
NCT01213238 is a clinical study titled "Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab". The goal of this clinical research study is to find the highest tolerable dose of the combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to patients with advanced cancer that has spread to the liver. The safety of these drug combinations will also be studied.
What is the current status of trial NCT01213238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2010-09-30. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT01213238?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT01213238?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.